Work

Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Year: 2002

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Arthritis & Rheumatism

DOI: 10.1002/art.10623

Authors: E. H. S. Choy, D. A. Isenberg, T. Garrood, S. Farrow, Y. Ioannou, H. Bird, N. Cheung, B. Williams, B. Hazleman, R. Price, K. Yoshizaki, N. Nishimoto, T. Kishimoto, G. S. Panayi

Institutions: King's College London, University College London, University of Leeds, Queen Mary's Hospital Sidcup, University Hospital of Wales, Addenbrooke's Hospital, Greenwich Hospital, The University of Osaka

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2000846863

FWCI: 20.2

Cites: 26

Cited by: 517

Related to: 10